Open access
Open access
Powered by Google Translator Translator

Covid-19: What is the evidence for the antiviral Paxlovid?

28 Apr, 2022 | 10:58h | UTC

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Related:

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.